Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Garon, Edward B.; Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh; Reck, Martin

doi:10.3389/fonc.2023.1247879

Cited by 6 publications

(3 citation statements)

References 65 publications

(362 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review of 10 studies suggests a numerical better PFS of docetaxel plus ramucirumab in prior exposed patients to ICI than in those naïve to these compounds (5.7 vs. 3.8 months) with statistical significance in two trials (p = 0.012 and p = 0.041). However, according to this publication, docetaxel plus ramucirumab could not offer OS advantage in ICI pretreated patients [33]. Hence, another retrospective observational study, including 1439 patients, reported that patients treated with chemotherapy with or without anti-angiogenics after ICIs had better ORR [HR 1.71 (1.19-2.46); p = 0.004] without any OS [HR 1.05 (0.86-1.28), p = 0.63] and PFS advantage [HR 0.95 (0.8-1.12), p = 0.55], compared to patients ICI-untreated [34].…”

Section: Chemotherapy Plus Anti-angiogenic Agentsmentioning

confidence: 87%

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Siringo,

Baena,

Bote de Cabo

et al. 2023

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionized the management of non-oncogene addicted non-small-cell lung cancer (NSCLC). Blocking the anti-PD-1 axis represents the current standard of care in the first-line setting, with drugs administered either as monotherapy or in combination with chemotherapy. Despite notable successes achieved with ICIs, most of their long-term benefits are restricted to approximately 20% of patients. Consequently, the post-failure treatment landscape after failure to first-line treatment remains a complex challenge. Currently, docetaxel remains the preferred option, although its benefits remain modest as most patients do not respond or progress promptly. In recent times, novel agents and treatment combinations have emerged, offering fresh opportunities to improve patient outcomes. ICIs combined either with antiangiogenic or other novel immunotherapeutic compounds have shown promising preliminary activity. However, more mature data concerning specific combinations do not support their benefit over standard of care. In addition, antibody–drug conjugates seem to be the most promising alternative among all available compounds according to already-published phase I/II data that will be confirmed in soon-to-be-published phase III trial data. In this report, we provide a comprehensive overview of the current second-line treatment options and discuss future therapeutic perspectives.

show abstract

Section: Chemotherapy Plus Anti-angiogenic Agentsmentioning

confidence: 87%

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Siringo,

Baena,

Bote de Cabo

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, there is no basis for implementing this type of treatment in clinical practice. There is a need for new drugs that act on other immunotherapy targets or combine known molecules with antiangiogenic drugs [53][54][55][56]. It is optimal to qualify patients for clinical trials with new drugs.…”

Section: Discussionmentioning

confidence: 99%

Rechallenge of immunotherapy in non-small cell lung cancer patients — navigating indications and evolving perspectives

Knetki-Wróblewska,

Chmielewska,

Wojas-Krawczyk

et al. 2024

Oncol Clin Pract

View full text Add to dashboard Cite

Indications for immunotherapy in patients with non-small-cell lung cancer (NSCLC) are expanding, with an increasing number of patients receiving immunotherapy in the perioperative setting or as consolidation of radiochemotherapy. Immune checkpoint inhibitor (ICI)-based regimens are also being used more and more often in the first-line systemic setting. However, in many cases, the efficacy of immunotherapy is limited, and it is necessary to determine the optimal sequence of systemic treatment. There is some theoretical rationale for repeated use of immune checkpoint inhibitors, but it is debatable which subgroups of patients are likely to benefit clinically from such treatment. Currently, data on the efficacy of immunotherapy retreatment are derived mainly from retrospective analyses and reviews of small subgroups of patients treated in clinical trials, making it difficult to draw reliable conclusions. There is a need for research identifying factors that will guide clinical decision-making, such as the time from the completion of immunotherapy, the initial response achieved, the expression of PD-L1, and others. It appears that patients who discontinued immunotherapy due to disease progression should not be requalified for treatment with currently available ICIs. Treatment in controlled clinical trials is the optimal strategy in such cases.

show abstract

“…The MW is 146 kDa, which is similar to bevacizumab. It is used mainly in oncological contexts, including gatric, colorectal, non-small cell lung cancers, and hepatocarcinoma [18][19][20]. The safety of intraocular injection of ramucirumab has not yet been extensively tested.…”

Section: Vegfi Belonging To the Antibodies/chimeric Proteins Categorymentioning

confidence: 99%

Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

Santorsola,

Capuozzo,

Nasti

et al. 2024

Cancers

View full text Add to dashboard Cite

The use of Vascular Endothelial Growth Factor inhibitors (VEGFi) has become prevalent in the field of medicine, given the high incidence of various pathological conditions necessitating VEGF inhibition within the general population. These conditions encompass a range of advanced neoplasms, such as colorectal cancer, non-small cell lung cancer, renal cancer, ovarian cancer, and others, along with ocular diseases. The utilization of VEGFi is not without potential risks and adverse effects, requiring healthcare providers to be well-prepared for identification and management. VEGFi can be broadly categorized into two groups: antibodies or chimeric proteins that specifically target VEGF (bevacizumab, ramucirumab, aflibercept, ranibizumab, and brolucizumab) and non-selective and selective small molecules (sunitinib, sorafenib, cabozantinib, lenvatinib, regorafenib, etc.) designed to impede intracellular signaling of the VEGF receptor (RTKi, receptor tyrosine kinase inhibitors). The presentation and mechanisms of adverse effects resulting from VEGFi depend primarily on this distinction and the route of drug administration (systemic or intra-vitreal). This review provides a thorough examination of the causes, recognition, management, and preventive strategies for VEGFi toxicities with the goal of offering support to oncologists in both clinical practice and the design of clinical trials.

show abstract

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Cited by 6 publications

References 65 publications

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Rechallenge of immunotherapy in non-small cell lung cancer patients — navigating indications and evolving perspectives

Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

Contact Info

Product

Resources

About